Titre : Inhibiteurs de la cyclooxygénase 2

Inhibiteurs de la cyclooxygénase 2 : Questions médicales fréquentes

Termes MeSH sélectionnés :

Sexual Partners
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Inhibiteurs de la cyclooxygénase 2 : Questions médicales les plus fréquentes", "headline": "Inhibiteurs de la cyclooxygénase 2 : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Inhibiteurs de la cyclooxygénase 2 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-07-12", "dateModified": "2025-04-08", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Inhibiteurs de la cyclooxygénase 2" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Inhibiteurs des cyclooxygénases", "url": "https://questionsmedicales.fr/mesh/D016861", "about": { "@type": "MedicalCondition", "name": "Inhibiteurs des cyclooxygénases", "code": { "@type": "MedicalCode", "code": "D016861", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D27.505.954.329.030.500" } } }, "about": { "@type": "MedicalCondition", "name": "Inhibiteurs de la cyclooxygénase 2", "alternateName": "Cyclooxygenase 2 Inhibitors", "code": { "@type": "MedicalCode", "code": "D052246", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Afshin Zarghi", "url": "https://questionsmedicales.fr/author/Afshin%20Zarghi", "affiliation": { "@type": "Organization", "name": "Department of Pharmaceutical Chemistry, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran." } }, { "@type": "Person", "name": "Rui Wang", "url": "https://questionsmedicales.fr/author/Rui%20Wang", "affiliation": { "@type": "Organization", "name": "Department of Gastroenterology, West China Hospital, Sichuan University, Chengdu, China." } }, { "@type": "Person", "name": "Mahsa Azami Movahed", "url": "https://questionsmedicales.fr/author/Mahsa%20Azami%20Movahed", "affiliation": { "@type": "Organization", "name": "Department of Pharmaceutical Chemistry, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran." } }, { "@type": "Person", "name": "Mohammad Mahboubi-Rabbani", "url": "https://questionsmedicales.fr/author/Mohammad%20Mahboubi-Rabbani", "affiliation": { "@type": "Organization", "name": "Islamic Azad University, Tehran Department of Medicinal Chemistry Tehran Iran." } }, { "@type": "Person", "name": "Ying Wang", "url": "https://questionsmedicales.fr/author/Ying%20Wang", "affiliation": { "@type": "Organization", "name": "College of Pharmacy, Pusan National University, Busan 46241, Republic of Korea." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "The Influence of Peers, Romantic Partners, and Families on Emerging Adults' Sexual Behavior.", "datePublished": "2022-12-05", "url": "https://questionsmedicales.fr/article/36469145", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s10508-022-02489-z" } }, { "@type": "ScholarlyArticle", "name": "The Effects of Medical Male Circumcision on Female Partners' Sexual and Reproductive Health.", "datePublished": "2022-11-11", "url": "https://questionsmedicales.fr/article/36367636", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s11904-022-00638-6" } }, { "@type": "ScholarlyArticle", "name": "Sexual Coercion, Intimate Partner Violence, and Homicide: A Scoping Literature Review.", "datePublished": "2023-02-01", "url": "https://questionsmedicales.fr/article/36722380", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1177/15248380221150474" } }, { "@type": "ScholarlyArticle", "name": "HIV serodiscordant sexual partners: social representations of health care professionals.", "datePublished": "2022-06-24", "url": "https://questionsmedicales.fr/article/35766755", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1590/0034-7167-2021-0867" } }, { "@type": "ScholarlyArticle", "name": "Partner presence in clinical conversations about sexual health: Breast cancer survivors', partners', and providers' perspectives of triadic interactions.", "datePublished": "2022-05-19", "url": "https://questionsmedicales.fr/article/35587166", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1080/07347332.2022.2068397" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Actions chimiques et utilisations", "item": "https://questionsmedicales.fr/mesh/D020164" }, { "@type": "ListItem", "position": 3, "name": "Actions pharmacologiques", "item": "https://questionsmedicales.fr/mesh/D020228" }, { "@type": "ListItem", "position": 4, "name": "Utilisations thérapeutiques", "item": "https://questionsmedicales.fr/mesh/D045506" }, { "@type": "ListItem", "position": 5, "name": "Antirhumatismaux", "item": "https://questionsmedicales.fr/mesh/D018501" }, { "@type": "ListItem", "position": 6, "name": "Anti-inflammatoires non stéroïdiens", "item": "https://questionsmedicales.fr/mesh/D000894" }, { "@type": "ListItem", "position": 7, "name": "Inhibiteurs des cyclooxygénases", "item": "https://questionsmedicales.fr/mesh/D016861" }, { "@type": "ListItem", "position": 8, "name": "Inhibiteurs de la cyclooxygénase 2", "item": "https://questionsmedicales.fr/mesh/D052246" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Inhibiteurs de la cyclooxygénase 2 - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Inhibiteurs de la cyclooxygénase 2", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-17", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Inhibiteurs de la cyclooxygénase 2", "description": "Comment diagnostiquer une inflammation nécessitant des COX-2 ?\nQuels tests sont utilisés pour évaluer l'efficacité des COX-2 ?\nLes COX-2 sont-ils prescrits pour toutes les douleurs ?\nComment différencier les douleurs inflammatoires des autres ?\nQuels signes cliniques indiquent l'utilisation des COX-2 ?", "url": "https://questionsmedicales.fr/mesh/D052246?mesh_terms=Sexual+Partners&page=2#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Inhibiteurs de la cyclooxygénase 2", "description": "Quels symptômes traitent les inhibiteurs de COX-2 ?\nLes COX-2 soulagent-ils la fièvre ?\nQuels effets secondaires peuvent survenir avec les COX-2 ?\nLes COX-2 affectent-ils l'humeur ?\nPeut-on ressentir des douleurs abdominales avec les COX-2 ?", "url": "https://questionsmedicales.fr/mesh/D052246?mesh_terms=Sexual+Partners&page=2#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Inhibiteurs de la cyclooxygénase 2", "description": "Comment prévenir les effets secondaires des COX-2 ?\nY a-t-il des mesures préventives avant de commencer les COX-2 ?\nLes patients à risque doivent-ils éviter les COX-2 ?\nComment surveiller l'efficacité des COX-2 ?\nLes changements de mode de vie aident-ils avec les COX-2 ?", "url": "https://questionsmedicales.fr/mesh/D052246?mesh_terms=Sexual+Partners&page=2#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Inhibiteurs de la cyclooxygénase 2", "description": "Quels médicaments sont des inhibiteurs de COX-2 ?\nComment les COX-2 sont-ils administrés ?\nLes COX-2 peuvent-ils être combinés avec d'autres médicaments ?\nQuelle est la durée du traitement avec les COX-2 ?\nLes COX-2 sont-ils disponibles sans ordonnance ?", "url": "https://questionsmedicales.fr/mesh/D052246?mesh_terms=Sexual+Partners&page=2#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Inhibiteurs de la cyclooxygénase 2", "description": "Quelles complications peuvent survenir avec les COX-2 ?\nLes COX-2 augmentent-ils le risque d'accidents vasculaires ?\nComment gérer les complications des COX-2 ?\nLes complications sont-elles fréquentes avec les COX-2 ?\nQuels signes indiquent une complication avec les COX-2 ?", "url": "https://questionsmedicales.fr/mesh/D052246?mesh_terms=Sexual+Partners&page=2#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Inhibiteurs de la cyclooxygénase 2", "description": "Quels facteurs augmentent le risque d'effets secondaires des COX-2 ?\nL'âge influence-t-il le risque avec les COX-2 ?\nLes femmes enceintes peuvent-elles utiliser des COX-2 ?\nLe tabagisme affecte-t-il l'utilisation des COX-2 ?\nLes antécédents familiaux influencent-ils le risque ?", "url": "https://questionsmedicales.fr/mesh/D052246?mesh_terms=Sexual+Partners&page=2#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une inflammation nécessitant des COX-2 ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Un diagnostic repose sur l'examen clinique et des tests d'imagerie pour évaluer l'inflammation." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour évaluer l'efficacité des COX-2 ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des échelles de douleur et des tests fonctionnels peuvent être utilisés pour évaluer l'efficacité." } }, { "@type": "Question", "name": "Les COX-2 sont-ils prescrits pour toutes les douleurs ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Non, ils sont généralement prescrits pour des douleurs inflammatoires spécifiques comme l'arthrite." } }, { "@type": "Question", "name": "Comment différencier les douleurs inflammatoires des autres ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Les douleurs inflammatoires sont souvent accompagnées de raideur matinale et d'enflure." } }, { "@type": "Question", "name": "Quels signes cliniques indiquent l'utilisation des COX-2 ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Des signes comme l'enflure, la chaleur et la douleur persistante peuvent indiquer leur utilisation." } }, { "@type": "Question", "name": "Quels symptômes traitent les inhibiteurs de COX-2 ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Ils traitent principalement la douleur et l'inflammation associées à des conditions comme l'arthrite." } }, { "@type": "Question", "name": "Les COX-2 soulagent-ils la fièvre ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Non, les inhibiteurs de COX-2 ne sont pas principalement utilisés pour traiter la fièvre." } }, { "@type": "Question", "name": "Quels effets secondaires peuvent survenir avec les COX-2 ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Les effets secondaires incluent des troubles gastro-intestinaux, des maux de tête et des vertiges." } }, { "@type": "Question", "name": "Les COX-2 affectent-ils l'humeur ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Ils ne sont pas connus pour affecter directement l'humeur, mais la douleur chronique peut le faire." } }, { "@type": "Question", "name": "Peut-on ressentir des douleurs abdominales avec les COX-2 ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des douleurs abdominales peuvent survenir en raison d'effets secondaires gastro-intestinaux." } }, { "@type": "Question", "name": "Comment prévenir les effets secondaires des COX-2 ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Pour prévenir les effets secondaires, il est conseillé de les prendre avec de la nourriture et de suivre les doses prescrites." } }, { "@type": "Question", "name": "Y a-t-il des mesures préventives avant de commencer les COX-2 ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un bilan de santé et une évaluation des antécédents médicaux sont recommandés." } }, { "@type": "Question", "name": "Les patients à risque doivent-ils éviter les COX-2 ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Les patients avec des antécédents de problèmes cardiaques doivent consulter un médecin avant de les utiliser." } }, { "@type": "Question", "name": "Comment surveiller l'efficacité des COX-2 ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "La surveillance peut inclure des évaluations régulières de la douleur et des tests de laboratoire." } }, { "@type": "Question", "name": "Les changements de mode de vie aident-ils avec les COX-2 ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un mode de vie sain peut améliorer l'efficacité des traitements anti-inflammatoires." } }, { "@type": "Question", "name": "Quels médicaments sont des inhibiteurs de COX-2 ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Des exemples incluent le célécoxib et le rofécoxib, utilisés pour traiter l'inflammation." } }, { "@type": "Question", "name": "Comment les COX-2 sont-ils administrés ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Ils sont généralement administrés par voie orale sous forme de comprimés ou de capsules." } }, { "@type": "Question", "name": "Les COX-2 peuvent-ils être combinés avec d'autres médicaments ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Oui, mais il est important de consulter un médecin pour éviter les interactions médicamenteuses." } }, { "@type": "Question", "name": "Quelle est la durée du traitement avec les COX-2 ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "La durée dépend de la condition traitée, mais elle doit être déterminée par un médecin." } }, { "@type": "Question", "name": "Les COX-2 sont-ils disponibles sans ordonnance ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Non, les inhibiteurs de COX-2 nécessitent généralement une prescription médicale." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec les COX-2 ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications peuvent inclure des problèmes gastro-intestinaux, des troubles cardiaques et des réactions allergiques." } }, { "@type": "Question", "name": "Les COX-2 augmentent-ils le risque d'accidents vasculaires ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains inhibiteurs de COX-2 peuvent augmenter le risque d'accidents vasculaires cérébraux." } }, { "@type": "Question", "name": "Comment gérer les complications des COX-2 ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "La gestion des complications nécessite une consultation médicale et un ajustement du traitement." } }, { "@type": "Question", "name": "Les complications sont-elles fréquentes avec les COX-2 ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Les complications ne sont pas fréquentes, mais elles peuvent survenir chez certains patients à risque." } }, { "@type": "Question", "name": "Quels signes indiquent une complication avec les COX-2 ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Des signes comme des douleurs thoraciques, des saignements gastro-intestinaux ou des éruptions cutanées doivent alerter." } }, { "@type": "Question", "name": "Quels facteurs augmentent le risque d'effets secondaires des COX-2 ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les antécédents de maladies cardiaques, d'ulcères ou d'allergies augmentent le risque." } }, { "@type": "Question", "name": "L'âge influence-t-il le risque avec les COX-2 ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les personnes âgées peuvent avoir un risque accru d'effets secondaires et de complications." } }, { "@type": "Question", "name": "Les femmes enceintes peuvent-elles utiliser des COX-2 ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "L'utilisation des COX-2 pendant la grossesse doit être évitée sauf si prescrite par un médecin." } }, { "@type": "Question", "name": "Le tabagisme affecte-t-il l'utilisation des COX-2 ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le tabagisme peut augmenter le risque de complications gastro-intestinales avec les COX-2." } }, { "@type": "Question", "name": "Les antécédents familiaux influencent-ils le risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents familiaux de maladies cardiaques peuvent augmenter le risque d'effets secondaires." } } ] } ] }

Sources (10000 au total)

The Effects of Medical Male Circumcision on Female Partners' Sexual and Reproductive Health.

Voluntary medical male circumcision (VMMC) reduces the risk of HIV acquisition by 60% among heterosexual men, provides protection against certain sexually transmitted infections (STI), and leads to pe... Systematic reviews find strong evidence for beneficial effects of VMMC on female sex partners risk of HPV, cervical dysplasia, cervical cancer, and with likely protection against trichomoniasis and ce...

HIV serodiscordant sexual partners: social representations of health care professionals.

to understand the structure of the social representations of health professionals from HIV/AIDS Specialized Care Services about HIV-positive partners.... this is a qualitative study, based on the structural aspect of Social Representations, developed in specialized services of the metropolitan area of a state in the Northeast Region. Fifty-one professi... the central nucleus was constituted by the terms "partnership", "love" and "fear", showing appreciation of meanings inherent to their beliefs, values and experiences that bring possibilities of reflec... the findings reinforce the impacts generated in the different segments of the lives of people living with HIV and in their emotional bonds. This highlights the need for the implementation of care stra...

Partner presence in clinical conversations about sexual health: Breast cancer survivors', partners', and providers' perspectives of triadic interactions.

Breast cancer survivors' (BCSs') sexual health (SH) clinical conversations are rarely studied from a dyadic perspective let alone from a triadic perspective. Using a triadic approach, we evaluated BCS... Qualitative approach using in-depth interviews.... 93 BCSs, partners, and providers involved in BCS care.... In-depth interviews with BCSs, partners, and providers explored triadic perspectives to understand factors informing BCSs' comfort level. Thematic analysis was used to analyze data.... Four themes characterize potential benefits of partner presence: 1) partner facilitates information exchange, 2) partner realizes BCS's SH concerns are "a real thing," 3) partner better understands SH... Providers should (1) initiate conversations about BCS comfort with partner presence, (2) be aware of the interaction between BCS primary and secondary goals, (3) consider how BCS/partner goal conflict...

Disability status, partner behavior, and the risk of sexual intimate partner violence in Uganda: An analysis of the demographic and health survey data.

Women with disabilities in developing countries experience significant marginalization, which negatively affects their reproductive health. This study examined the association between disability statu... The study, which was based on a merged dataset of 2006, 2011 and 2016 Uganda Demographic Surveys, used a weighted sample of 9689 cases of married women selected for the domestic violence modules. Data... Sexual IPV was higher among women with disabilities (25% compared to 18%). Disability status predicted sexual intimate partner violence with higher odds among women with disabilities (aOR = 1.51; 95% ... Determinants of sexual intimate partner violence mainly relate to partners' behaviors and the socialization process. Addressing sexual intimate partner violence requires prioritizing partners' behavio...

Sexual Violence Perpetration Against Intimate Partners: Current Progress and Future Directions.

The literature on sexual violence perpetration against an intimate partner is reviewed and synthesized. Intimate partner sexual violence (IPSV) is compared to other forms of interpersonal violence, an... Recent research suggests the perpetration of IPSV is heterogeneous in nature, and individuals who perpetrate IPSV present with criminogenic needs consistent with exclusively sexual and violent offende...

Reproductive and sexual health effects of intimate partner violence: A longitudinal and intergenerational analysis.

To examine the prevalence, pattern and predictors of sexual and reproductive adversity among Australian women who report intimate partner violence (IPV).... Repeat measure design employing two cohorts (born between the years of 1973-78 and 1989-95) from the National Australian Longitudinal Study on Women's Health. Logistic regression was employed to exami... IPV exposure was associated with increased odds of experiencing a range of sexual and reproductive health outcomes, including STI, endometriosis, infertility, termination and miscarriage, which increa... Women who experience IPV are at significant risk of adverse sexual and reproductive outcomes. Healthcare professionals working with women who have diagnosed sexual and reproductive issues should inqui...